| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Institute of General Pathology
2 Institute of Neurology, Catholic University, Rome
and3 Department of Cell Biology and Physiology, University of L'Aquila, L'Aquila, Italy
The effect of the organic sulphated polyanions, pentosan sulphate (SP54), dextran sulphate 500 (DS500) and suramin, have been tested on golden Syrian hamsters infected with the 263K strain of scrapie by the intraperitoneal (i.p.) or the intracerebral route. SP54 had the greatest effect in prolonging the incubation period of the disease when administered within 2 h of the i.p. inoculum. The same amount of SP54 given 24 h after scrapie inoculation had a potent effect in some animals and no effect in others. This result suggests that SP54 inhibits the uptake of the scrapie agent into the nerve endings and/or carrier cells at the site of the inoculum, i.e. the peritoneum, and that this event occurs in about 24 h. DS500 had a similar although less potent effect (22·4 days delay during the incubation period) than SP54 (54·4 days) when administered within 2 h of scrapie injection by the i.p. route, and suramin had only a minimal effect (10 days). This study suggests that treatment of scrapie and related spongiform encephalopathies of animals and man is possible only before the agent has reached the clinical target areas of the brain.
Received 9 September 1991;
accepted 6 November 1991.
This article has been cited by other articles:
|
|
 |
|
  C.-H. Song, H. Furuoka, C.-L. Kim, M. Ogino, A. Suzuki, R. Hasebe, and M. Horiuchi Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice J. Gen. Virol., June 1, 2008; 89(6): 1533 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Prior, S. Lehmann, M.-S. Sy, B. Molloy, and H. E. M. McMahon Cyclodextrins Inhibit Replication of Scrapie Prion Protein in Cell Culture J. Virol., October 15, 2007; 81(20): 11195 - 11207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Larramendy-Gozalo, A. Barret, E. Daudigeos, E. Mathieu, L. Antonangeli, C. Riffet, E. Petit, D. Papy-Garcia, D. Barritault, P. Brown, et al. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases J. Gen. Virol., March 1, 2007; 88(3): 1062 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R Trevitt and J. Collinge A systematic review of prion therapeutics in experimental models Brain, September 1, 2006; 129(9): 2241 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kocisko, A. Vaillant, K. S. Lee, K. M. Arnold, N. Bertholet, R. E. Race, E. A. Olsen, J.-M. Juteau, and B. Caughey Potent Antiscrapie Activities of Degenerate Phosphorothioate Oligonucleotides Antimicrob. Agents Chemother., March 1, 2006; 50(3): 1034 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hijazi, Z. Kariv-Inbal, M. Gasset, and R. Gabizon PrPSc Incorporation to Cells Requires Endogenous Glycosaminoglycan Expression J. Biol. Chem., April 29, 2005; 280(17): 17057 - 17061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barret, L. Forestier, J.-P. Deslys, R. Julien, and P. F. Gallet Glycosylation-related Gene Expression in Prion Diseases: PrPSc ACCUMULATION IN SCRAPIE INFECTED GT1 CELLS DEPENDS ON {beta}-1,4-LINKED GalNAc-4-SO4 HYPOSULFATION J. Biol. Chem., March 18, 2005; 280(11): 10516 - 10523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-L. Kim, A. Karino, N. Ishiguro, M. Shinagawa, M. Sato, and M. Horiuchi Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation J. Gen. Virol., November 1, 2004; 85(11): 3473 - 3482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ertmer, S. Gilch, S.-W. Yun, E. Flechsig, B. Klebl, M. Stein-Gerlach, M. A. Klein, and H. M. Schatzl The Tyrosine Kinase Inhibitor STI571 Induces Cellular Clearance of PrPSc in Prion-infected Cells J. Biol. Chem., October 1, 2004; 279(40): 41918 - 41927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Doh-ura, K. Ishikawa, I. Murakami-Kubo, K. Sasaki, S. Mohri, R. Race, and T. Iwaki Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal Models J. Virol., May 15, 2004; 78(10): 4999 - 5006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Ben-Zaken, S. Tzaban, Y. Tal, L. Horonchik, J. D. Esko, I. Vlodavsky, and A. Taraboulos Cellular Heparan Sulfate Participates in the Metabolism of Prions J. Biol. Chem., October 10, 2003; 278(41): 40041 - 40049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Adjou, S. Simoneau, N. Sales, F. Lamoury, D. Dormont, D. Papy-Garcia, D. Barritault, J.-P. Deslys, and C. I. Lasmezas A novel generation of heparan sulfate mimetics for the treatment of prion diseases J. Gen. Virol., September 1, 2003; 84(9): 2595 - 2603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barret, F. Tagliavini, G. Forloni, C. Bate, M. Salmona, L. Colombo, A. De Luigi, L. Limido, S. Suardi, G. Rossi, et al. Evaluation of Quinacrine Treatment for Prion Diseases J. Virol., August 1, 2003; 77(15): 8462 - 8469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dormont Approaches to prophylaxis and therapy: An investigation into prion disease diversity Br. Med. Bull., June 1, 2003; 66(1): 281 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Sigurdsson, D. R. Brown, M. Daniels, R. J. Kascsak, R. Kascsak, R. Carp, H. C. Meeker, B. Frangione, and T. Wisniewski Immunization Delays the Onset of Prion Disease in Mice Am. J. Pathol., July 1, 2002; 161(1): 13 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Brown Drug therapy in human and experimental transmissible spongiform encephalopathy Neurology, June 25, 2002; 58(12): 1720 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Warner, C. Hundt, S. Weiss, and J. E. Turnbull Identification of the Heparan Sulfate Binding Sites in the Cellular Prion Protein J. Biol. Chem., May 17, 2002; 277(21): 18421 - 18430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Rudyk, S. Vasiljevic, R. M. Hennion, C. R. Birkett, J. Hope, and I. H. Gilbert Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells J. Gen. Virol., April 1, 2000; 81(4): 1155 - 1164. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Supattapone, H.-O. B. Nguyen, F. E. Cohen, S. B. Prusiner, and M. R. Scott Elimination of prions by branched polyamines and implications for therapeutics PNAS, December 7, 1999; 96(25): 14529 - 14534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Demaimay, R. Race, and B. Chesebro Effectiveness of Polyene Antibiotics in Treatment of Transmissible Spongiform Encephalopathy in Transgenic Mice Expressing Syrian Hamster PrP Only in Neurons J. Virol., April 1, 1999; 73(4): 3511 - 3513. [Abstract] [Full Text]
|
|
|
|
|
|
K. Adjou, R Demaimay, J. Deslys, C. Lasmezas, V Beringue, S Demart, F Lamoury, M Seman, and D Dormont MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie J. Gen. Virol., April 1, 1999; 80(4): 1079 - 1085. [Abstract]
|
|
|
|
|
|
S.-L. Shyng, S. Lehmann, K. L. Moulder, and D. A. Harris Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrP^C, in Cultured Cells J. Biol. Chem., December 15, 1995; 270(50): 30221 - 30229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Shaked, Z. Meiner, I. Avraham, A. Taraboulos, and R. Gabizon Reconstitution of Prion Infectivity from Solubilized Protease-resistant PrP and Nonprotein Components of Prion Rods J. Biol. Chem., April 20, 2001; 276(17): 14324 - 14328. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
